Demand for Hypertrophic Cardiomyopathy Therapeutics Expected to Increase Post Approval of Novel Drugs, Says TMR The global hypertrophic cardiomyopathy (HCM) therapeutics market is dominated by companies exhibiting high sales. However, generic manufacturers are making their presence felt in the market gradually. As per Transparency Market Research (TMR), the top three companies in the market, Sanofi S.A., Pfizer, Inc., and Merck & Co., accounted for a share of over 64.5%, which points toward a highly consolidated vendor landscape. Intense competition exists among the top companies in the market. These enterprises are mainly focusing on expanding and differentiating their product portfolio to enjoy sustainable growth.
Demand for HCM Therapeutics Surges due to Increasing Incidence of Congestive Heart Failure “The prevalence of chronic cardiovascular ailments is fueling demand for effective treatment, which has been translating into lucrative sales opportunities for hypertrophic cardiomyopathy therapeutics,” said a lead TMR analyst. Heart diseases make one of the most common causes of death in both men and women around the world. According to TMR, the rising incidence of congestive heart failure considerably fuels demand for effective medications. This creates attractive opportunities for sales of hypertrophic cardiomyopathy therapeutics. "Besides this, successful interventions conducted across several countries to spread awareness about hypertrophic cardiomyopathy have also aided the expansion of the HCM therapeutics market,” said the TMR analyst. Furthermore, patients are now more aware about the latest medical advances, which augurs well for the market. ECG screening is the most efficient technology for diagnosing HCM. The success demonstrated by this technology has significantly contributed in fuelling demand for HCM therapeutics. Read Full Report: http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathytherapeutics-market.html Rising Penetration of Advanced Medical Devices to Threaten Market Growth Despite witnessing positive growth opportunities, the rising penetration of medical devices such as pacemakers and defibrillators in the healthcare sector has been inhibiting the HCM therapeutics market’s trajectory. Demand for gene therapy and implantable medical devices is
rising as patients gain adequate knowledge about positive results offered by such advanced medical devices. The increasing acceptance of these medical devices could limit the scope of expansion for the HCM therapeutics market. Nevertheless, drugs created specifically for the treatment of hypertrophic cardiomyopathy are yet to find approval. Once approved, this indication will bolster sales opportunities for the market players. Additionally, due to the high prevalence of unmet medical needs across Asia Pacific and the increasing medical expenditure in the region also boosts prospects for the HCM therapeutics market. Regionally, North America holds the largest share in the global HCM therapeutics market. However, as per TMR, the market is also expected to witness strong growth in Asia Pacific and Rest of the World. The Asia Pacific HCM therapeutics market is poised to expand at 2.9% CAGR between 2015 and 2023. By drug class, the market was led by calcium channel blockers in 2014. By drug class, the calcium channel blockers is expected to dominate the market. It held over 37.4% of the HCM therapeutics market in 2014. Request For Discount On This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=7553 TMR estimates the overall value of the global hypertrophic cardiomyopathy therapeutics market at US$1.2 bn in 2014. Exhibiting a moderate CAGR of 1.4% from 2015 to 2023, the market is expected to reach US$1.3 bn by the end of 2023. This review is based on information published by TMR, in a report titled “Hypertrophic Cardiomyopathy Therapeutics (HCM) Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 – 2023.” Key Takeaways: Demand for effective HCM therapeutics to grow as incidence of heart failure rises around the world • Calcium channel blockers emerged as dominant drug class in 2014 with a share of 37.4% • Asia Pacific to exhibit fastest CAGR of 2.9% between 2015 and 2023 The report segments the global HCM therapeutics market as: •
Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class • Beta Adrenergic Blocking Agents • Calcium Channel Blockers • Antiarrhythmic Agents • Anticoagulants Global Hypertrophic Cardiomyopathy Therapeutics, by Geography
•
•
•
•
North America ◦ U.S. ◦ Canada Europe ◦ U.K. ◦ Germany ◦ Rest of Europe Asia Pacific ◦ India ◦ Japan ◦ Rest of Asia Pacific Rest of the World ◦ Latin America ◦ Middle East ◦ Africa
About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com